Floatz logo

Denileukin Diftitox

Lymphoma, Low-grade

Eisai Inc.protein_peptidePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lymphoma, Low-grade cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Eisai Inc.
Phase 2B
(+)-VINCRISTINE
Eisai Inc.
Phase 2B
Inno-206
Eisai Inc.
Phase 2B

Same molecule, other indications

Denileukin Diftitox is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
62 / 100
View asset →
Sezary syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →